ロード中...

Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4(+)CD25(+)FOXP3(+) Regulatory T-Cells

OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent graft rejection in humans, which is considered permissive for tolerance induction. Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal f...

詳細記述

保存先:
書誌詳細
主要な著者: Monti, Paolo, Scirpoli, Miriam, Maffi, Paola, Piemonti, Lorenzo, Secchi, Antonio, Bonifacio, Ezio, Roncarolo, Maria-Grazia, Battaglia, Manuela
フォーマット: Artigo
言語:Inglês
出版事項: American Diabetes Association 2008
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518485/
https://ncbi.nlm.nih.gov/pubmed/18559659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db08-0138
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!